Related Experiment Video

Updated: Aug 23, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease

Lillian Sung1, Paul C Nathan, Beverly Lange

  • 1Department of Pediatrics, University of Toronto, Ontario, Canada. Lillian.sung@sickkids.ca

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|August 18, 2004
PubMed

Insights

Prophylactic colony-stimulating factors (CSFs) significantly reduced febrile neutropenia and hospitalization duration in pediatric cancer patients. However, CSFs did not impact infection-related mortality in this patient group.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Pharmacology

Background:

  • Febrile neutropenia is a serious complication in children undergoing cancer treatment.
  • Hematopoietic colony-stimulating factors (CSFs) are used to mitigate neutropenia.
  • Evidence on the efficacy of prophylactic CSFs in pediatric cancer patients requires synthesis.

Purpose of the Study:

  • To evaluate the effectiveness of prophylactic colony-stimulating factors (CSFs) in reducing febrile neutropenia in pediatric cancer patients.
  • To assess the impact of CSFs on hospitalization duration, infection rates, antibiotic use, and infection-related mortality.
  • To synthesize existing evidence through a meta-analysis of randomized controlled trials.

Main Methods:

  • Meta-analysis of randomized controlled trials involving pediatric cancer patients receiving prophylactic CSFs.
  • Inclusion criteria required randomization to CSFs versus placebo or no therapy.
  • Chemotherapy regimens were identical in both arms; studies focused on prophylactic CSF administration before neutropenic events.

Main Results:

  • CSFs demonstrated a significant reduction in febrile neutropenia (rate ratio, 0.80; P =.01) and hospitalization length (weighted mean difference, -1.9 days; P <.00001).
  • A significant decrease was observed in documented infections (rate ratio, 0.78; P =.02) and amphotericin B use (rate ratio, 0.50; P =.02).
  • No significant difference was found in parenteral antibiotic duration or infection-related mortality (rate ratio, 1.02; P =.97).

Conclusions:

  • Prophylactic CSFs are associated with a 20% reduction in febrile neutropenia and shorter hospital stays in children with cancer.
  • While CSFs improve certain outcomes, they do not appear to reduce infection-related mortality.
  • Further research may be warranted to optimize CSF use in pediatric oncology.
Abstract

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...